- Home
- TIL vs GOSS Comparison
TIL vs GOSS Comparison
Compare TIL & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- GOSS
- Stock Information
- Founded
- TIL 2018
- GOSS 2015
- Country
- TIL United States
- GOSS United States
- Employees
- TIL N/A
- GOSS N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- GOSS Health Care
- Exchange
- TIL Nasdaq
- GOSS Nasdaq
- Market Cap
- TIL 230.1M
- GOSS 262.5M
- IPO Year
- TIL 2021
- GOSS 2019
- Fundamental
- Price
- TIL $22.62
- GOSS $1.30
- Analyst Decision
- TIL Buy
- GOSS Strong Buy
- Analyst Count
- TIL 5
- GOSS 4
- Target Price
- TIL $119.00
- GOSS $7.75
- AVG Volume (30 Days)
- TIL 387.8K
- GOSS 2.6M
- Earning Date
- TIL 08-12-2025
- GOSS 08-11-2025
- Dividend Yield
- TIL N/A
- GOSS N/A
- EPS Growth
- TIL N/A
- GOSS N/A
- EPS
- TIL N/A
- GOSS N/A
- Revenue
- TIL N/A
- GOSS $124,590,000.00
- Revenue This Year
- TIL N/A
- GOSS N/A
- Revenue Next Year
- TIL N/A
- GOSS $91.14
- P/E Ratio
- TIL N/A
- GOSS N/A
- Revenue Growth
- TIL N/A
- GOSS N/A
- 52 Week Low
- TIL $9.62
- GOSS $0.66
- 52 Week High
- TIL $92.00
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- TIL 40.10
- GOSS 48.00
- Support Level
- TIL $25.80
- GOSS $1.20
- Resistance Level
- TIL $23.30
- GOSS $1.44
- Average True Range (ATR)
- TIL 3.63
- GOSS 0.09
- MACD
- TIL -1.84
- GOSS -0.02
- Stochastic Oscillator
- TIL 1.91
- GOSS 10.42
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.